Gross Profit: Revenues from operations less the associated costs.
Xilio Therapeutics, Inc. (XLO) had Gross Profit of $12.65M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$12.65M |
|
$-9.53M |
|
-- |
|
|
Gross Profit |
$12.65M |
$26.76M |
|
$-14.11M |
|
$4.58M |
|
$-9.53M |
|
$-9.53M |
|
$-9.53M |
|
$-9.53M |
|
$-9.53M |
|
$-9.53M |
|
$-14.11M |
|
$-13.77M |
|
16.35M |
|
16.35M |
|
$-0.58 |
|
$-0.58 |
|
| Balance Sheet Financials | |
$154.21M |
|
$3.68M |
|
$9.28M |
|
$163.49M |
|
$42.96M |
|
-- |
|
$47.98M |
|
$90.94M |
|
$72.55M |
|
$72.55M |
|
$72.55M |
|
5.78M |
|
| Cash Flow Statement Financials | |
$-22.34M |
|
$-0.56M |
|
$35.71M |
|
$139.34M |
|
$152.15M |
|
$12.81M |
|
$2.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.59 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-111.58% |
|
-111.58% |
|
-- |
|
-75.34% |
|
-75.34% |
|
$-22.90M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
-- |
|
-- |
|
-- |
|
-13.14% |
|
-13.14% |
|
-5.83% |
|
-13.14% |
|
$12.54 |
|
$-1.40 |
|
$-1.37 |
|